Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1β

Kristin R. Coulter, Elizabeth D. Allen, Judy Hart, Mark D. Wewers, Robert G. Castile, Daren L. Knoell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Interleukin-1β (IL-1β) and neutrophil elastase (NE) are present in the epithelial lining fluid (ELF) of patients with cystic fibrosis (CF). Both factors activate surrounding cells including lung epithelial cells, causing release of IL-8, a potent chemoattractant for neutrophils. Previous studies showed upregulation of IL-8 release by lung epithelial cells as a function of NE in CF; however, few studies addressed the relationship between IL-1β and activation of lung epithelial cells in CF lungs. Confluent layers of A549 cells, a type II-like human lung epithelial cell line, were incubated overnight with IL-1β (0-5 ng/ml) or NE (100 nM), and supernatants were analyzed for IL-8 by enzyme-linked immunosorbent assay (ELISA). Both IL-1β and NE led to a significant increase in IL-8: 12.8 ± 2.8 ng/ml and 0.8 ± 0.3 ng/ml, respectively. Next, bronchoalveolar lavage (BAL) samples were obtained from one healthy adult volunteer and six patients with CF and measured for IL-8 and IL-1β concentrations by ELISA. Both IL-8 (range 169.00 ± 56.57 to 1742.04 ± 338.98 pg/ml) and IL-1β (range 0-24.26 ± 0.52 pg/ml) were detected in CF specimens, whereas neither was detected in the volunteer's specimen. Normal and CF BALs then were incubated overnight at a 1:10 dilution with confluent A549 cells. Analysis by ELISA of cell-free supernatants revealed increased IL-8 production from cells stimulated with CF BALs only. Similar experiments were performed with BAL supernatants that had been incubated with soluble IL-1 type II receptor, soluble IL-1 receptor antagonist, or a peptide inhibitor of NE. Addition of IL-1 inhibitors had a marginal effect on the amount of IL-8 release after incubation with CF BAL samples, whereas inhibition of NE had no effect. Our results indicate that other factors present in ELF in CF account for IL-8 release from lung epithelial cells.

Original languageEnglish (US)
Pages (from-to)64-74
Number of pages11
JournalPharmacotherapy
Volume20
Issue number1 I
DOIs
StatePublished - Jan 1 2000

Fingerprint

Interleukin-8
Interleukin-1
Cystic Fibrosis
Epithelium
Leukocyte Elastase
Lung
Epithelial Cells
Bronchoalveolar Lavage
Dimercaprol
Enzyme-Linked Immunosorbent Assay
Interleukin-1 Type II Receptors
Secretory Proteinase Inhibitory Proteins
Interleukin-1 Receptors
Chemotactic Factors
Volunteers
Healthy Volunteers
Neutrophils
Up-Regulation
Cell Line
Peptides

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1β. / Coulter, Kristin R.; Allen, Elizabeth D.; Hart, Judy; Wewers, Mark D.; Castile, Robert G.; Knoell, Daren L.

In: Pharmacotherapy, Vol. 20, No. 1 I, 01.01.2000, p. 64-74.

Research output: Contribution to journalArticle

Coulter, Kristin R. ; Allen, Elizabeth D. ; Hart, Judy ; Wewers, Mark D. ; Castile, Robert G. ; Knoell, Daren L. / Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1β. In: Pharmacotherapy. 2000 ; Vol. 20, No. 1 I. pp. 64-74.
@article{14d59c55462c4c1a806df0530ae4995f,
title = "Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1β",
abstract = "Interleukin-1β (IL-1β) and neutrophil elastase (NE) are present in the epithelial lining fluid (ELF) of patients with cystic fibrosis (CF). Both factors activate surrounding cells including lung epithelial cells, causing release of IL-8, a potent chemoattractant for neutrophils. Previous studies showed upregulation of IL-8 release by lung epithelial cells as a function of NE in CF; however, few studies addressed the relationship between IL-1β and activation of lung epithelial cells in CF lungs. Confluent layers of A549 cells, a type II-like human lung epithelial cell line, were incubated overnight with IL-1β (0-5 ng/ml) or NE (100 nM), and supernatants were analyzed for IL-8 by enzyme-linked immunosorbent assay (ELISA). Both IL-1β and NE led to a significant increase in IL-8: 12.8 ± 2.8 ng/ml and 0.8 ± 0.3 ng/ml, respectively. Next, bronchoalveolar lavage (BAL) samples were obtained from one healthy adult volunteer and six patients with CF and measured for IL-8 and IL-1β concentrations by ELISA. Both IL-8 (range 169.00 ± 56.57 to 1742.04 ± 338.98 pg/ml) and IL-1β (range 0-24.26 ± 0.52 pg/ml) were detected in CF specimens, whereas neither was detected in the volunteer's specimen. Normal and CF BALs then were incubated overnight at a 1:10 dilution with confluent A549 cells. Analysis by ELISA of cell-free supernatants revealed increased IL-8 production from cells stimulated with CF BALs only. Similar experiments were performed with BAL supernatants that had been incubated with soluble IL-1 type II receptor, soluble IL-1 receptor antagonist, or a peptide inhibitor of NE. Addition of IL-1 inhibitors had a marginal effect on the amount of IL-8 release after incubation with CF BAL samples, whereas inhibition of NE had no effect. Our results indicate that other factors present in ELF in CF account for IL-8 release from lung epithelial cells.",
author = "Coulter, {Kristin R.} and Allen, {Elizabeth D.} and Judy Hart and Wewers, {Mark D.} and Castile, {Robert G.} and Knoell, {Daren L.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1592/phco.20.1.64.34655",
language = "English (US)",
volume = "20",
pages = "64--74",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1 I",

}

TY - JOUR

T1 - Induction of interleukin-8 release by lung epithelium with cystic fibrosis epithelial lining fluid is marginally affected by inhibitors of interleukin-1β

AU - Coulter, Kristin R.

AU - Allen, Elizabeth D.

AU - Hart, Judy

AU - Wewers, Mark D.

AU - Castile, Robert G.

AU - Knoell, Daren L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Interleukin-1β (IL-1β) and neutrophil elastase (NE) are present in the epithelial lining fluid (ELF) of patients with cystic fibrosis (CF). Both factors activate surrounding cells including lung epithelial cells, causing release of IL-8, a potent chemoattractant for neutrophils. Previous studies showed upregulation of IL-8 release by lung epithelial cells as a function of NE in CF; however, few studies addressed the relationship between IL-1β and activation of lung epithelial cells in CF lungs. Confluent layers of A549 cells, a type II-like human lung epithelial cell line, were incubated overnight with IL-1β (0-5 ng/ml) or NE (100 nM), and supernatants were analyzed for IL-8 by enzyme-linked immunosorbent assay (ELISA). Both IL-1β and NE led to a significant increase in IL-8: 12.8 ± 2.8 ng/ml and 0.8 ± 0.3 ng/ml, respectively. Next, bronchoalveolar lavage (BAL) samples were obtained from one healthy adult volunteer and six patients with CF and measured for IL-8 and IL-1β concentrations by ELISA. Both IL-8 (range 169.00 ± 56.57 to 1742.04 ± 338.98 pg/ml) and IL-1β (range 0-24.26 ± 0.52 pg/ml) were detected in CF specimens, whereas neither was detected in the volunteer's specimen. Normal and CF BALs then were incubated overnight at a 1:10 dilution with confluent A549 cells. Analysis by ELISA of cell-free supernatants revealed increased IL-8 production from cells stimulated with CF BALs only. Similar experiments were performed with BAL supernatants that had been incubated with soluble IL-1 type II receptor, soluble IL-1 receptor antagonist, or a peptide inhibitor of NE. Addition of IL-1 inhibitors had a marginal effect on the amount of IL-8 release after incubation with CF BAL samples, whereas inhibition of NE had no effect. Our results indicate that other factors present in ELF in CF account for IL-8 release from lung epithelial cells.

AB - Interleukin-1β (IL-1β) and neutrophil elastase (NE) are present in the epithelial lining fluid (ELF) of patients with cystic fibrosis (CF). Both factors activate surrounding cells including lung epithelial cells, causing release of IL-8, a potent chemoattractant for neutrophils. Previous studies showed upregulation of IL-8 release by lung epithelial cells as a function of NE in CF; however, few studies addressed the relationship between IL-1β and activation of lung epithelial cells in CF lungs. Confluent layers of A549 cells, a type II-like human lung epithelial cell line, were incubated overnight with IL-1β (0-5 ng/ml) or NE (100 nM), and supernatants were analyzed for IL-8 by enzyme-linked immunosorbent assay (ELISA). Both IL-1β and NE led to a significant increase in IL-8: 12.8 ± 2.8 ng/ml and 0.8 ± 0.3 ng/ml, respectively. Next, bronchoalveolar lavage (BAL) samples were obtained from one healthy adult volunteer and six patients with CF and measured for IL-8 and IL-1β concentrations by ELISA. Both IL-8 (range 169.00 ± 56.57 to 1742.04 ± 338.98 pg/ml) and IL-1β (range 0-24.26 ± 0.52 pg/ml) were detected in CF specimens, whereas neither was detected in the volunteer's specimen. Normal and CF BALs then were incubated overnight at a 1:10 dilution with confluent A549 cells. Analysis by ELISA of cell-free supernatants revealed increased IL-8 production from cells stimulated with CF BALs only. Similar experiments were performed with BAL supernatants that had been incubated with soluble IL-1 type II receptor, soluble IL-1 receptor antagonist, or a peptide inhibitor of NE. Addition of IL-1 inhibitors had a marginal effect on the amount of IL-8 release after incubation with CF BAL samples, whereas inhibition of NE had no effect. Our results indicate that other factors present in ELF in CF account for IL-8 release from lung epithelial cells.

UR - http://www.scopus.com/inward/record.url?scp=0033989266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033989266&partnerID=8YFLogxK

U2 - 10.1592/phco.20.1.64.34655

DO - 10.1592/phco.20.1.64.34655

M3 - Article

C2 - 10641976

AN - SCOPUS:0033989266

VL - 20

SP - 64

EP - 74

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1 I

ER -